Laimei Pharmaceutical (300006.SZ) subsidiary's phenelidone API approved for listing

Zhitongcaijing · 1d ago

Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (Laimei Longyu for short), a wholly-owned subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” approved and issued by the State Drug Administration. Fenelidone is a nonsteroidal selective halocorticoid receptor (MR) antagonist whose formulation is used to treat adult patients with chronic kidney disease associated with type 2 diabetes.